About Passage Bio
Passage Bio is a company based in Philadelphia (United States) founded in 2017 by Stephen Squinto.. Passage Bio has raised $225.5 million across 3 funding rounds from investors including New Leaf Venture Partners, Orbimed and Frazier Healthcare Partners. The company has 60 employees as of December 31, 2024. Passage Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Philadelphia, United States
- Employees 60 as on 31 Dec, 2024
- Founders Stephen Squinto
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Passage Bio, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-64.77 M36.54as on Dec 31, 2024
-
EBITDA
$-62.09 M35.61as on Dec 31, 2024
-
Total Equity Funding
$225.5 M (USD)
in 3 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Sep 09, 2021
-
Investors
New Leaf Venture Partners
& 10 more
-
Employee Count
60
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Passage Bio
Passage Bio is a publicly listed company on the NASDAQ with ticker symbol PASG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Passage Bio
Passage Bio has successfully raised a total of $225.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(14 Feb 2019)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Post-IPO - Passage Bio | Valuation |
investors |
|
| Sep, 2019 | Amount | Series B - Passage Bio | Valuation | Access Biotechnology | |
| Feb, 2019 | Amount | Series A - Passage Bio | Valuation | Orbimed |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Passage Bio
Passage Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Orbimed and Frazier Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Passage Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Passage Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Passage Bio Comparisons
Competitors of Passage Bio
Passage Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Passage Bio
Frequently Asked Questions about Passage Bio
When was Passage Bio founded?
Passage Bio was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Passage Bio located?
Passage Bio is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Who is the current CEO of Passage Bio?
William Chou is the current CEO of Passage Bio.
Is Passage Bio a funded company?
Passage Bio is a funded company, having raised a total of $225.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $115.5M, raised on Feb 14, 2019.
How many employees does Passage Bio have?
As of Dec 31, 2024, the latest employee count at Passage Bio is 60.
What does Passage Bio do?
Passage Bio was founded in 2017 in Philadelphia, United States, within the biotechnology sector. AAV-delivered therapeutics are developed for rare monogenic central nervous system diseases. Lead programs are directed toward GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Operations center on advancing gene therapy solutions for these conditions, with research and development conducted in the U.S. geographic area.
Who are the top competitors of Passage Bio?
Passage Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Is Passage Bio publicly traded?
Yes, Passage Bio is publicly traded on NASDAQ under the ticker symbol PASG.
Who are Passage Bio's investors?
Passage Bio has 11 investors. Key investors include New Leaf Venture Partners, Orbimed, Frazier Healthcare Partners, Versant Ventures, and Lilly Asia Ventures.
What is Passage Bio's ticker symbol?
The ticker symbol of Passage Bio is PASG on NASDAQ.